Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Clinical treatment programs	$ 47	$ 36	$ 83	$ 112
Total revenues	47	36	83	112
Costs and expenses:
Production costs	507	294	879	617
Research and development	2,439	2,330	5,113	4,656
General and administrative	2,002	2,497	3,915	5,036
Total costs and expenses	4,948	5,121	9,907	10,309
Operating loss	(4,901)	(5,085)	(9,824)	(10,197)
Interest expense	0	(3)	(2)	(6)
Interest and other income/expense	56	131	162	284
Redeemable warrants valuation adjustment	0	1	0	1
Gain from sale of income tax net operating losses	0	0	1,374	1,126
Net loss	(4,845)	(4,956)	(8,290)	(8,792)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	(137)	147	(26)	168
Net comprehensive loss	$ (4,982)	$ (4,809)	$ (8,316)	$ (8,624)
Basic and diluted loss per share (usd per share)	$ (0.02)	$ (0.03)	$ (0.04)	$ (0.05)
Weighted average shares outstanding, basic and diluted (shares)	236,149,999	185,749,722	224,954,200	181,265,253